Healthcare stocks were rising pre-bell Tuesday, with the State Street Health Care Select Sector SPDR ETF (XLV) 0.4% higher and the iShares Biotechnology ETF (IBB) advancing by 1.1%.
TG Therapeutics (TGTX) shares were up more than 3% after the company said it has started a phase 2 trial evaluating BRIUMVI as a maintenance therapy following induction with efgartigimod in adult patients with myasthenia gravis, a chronic autoimmune neuromuscular disease.